Karyopharm Therapeutics | KPTI - Debt


Karyopharm Therapeutics reported $264.09M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Abbott USD 12.94B 496M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Incyte USD 41.27M 1.14M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.85T 208B Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
TG Therapeutics USD 245.34M 8.38M Sep/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025